Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry - Rivaroxaban cohort

Trial Profile

Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registry - Rivaroxaban cohort

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms JACRE-R
  • Sponsors Bayer Yakuhin
  • Most Recent Events

    • 28 Sep 2017 Results assessing the effects and risks of heparin bridging and different patterns of interruption/resumption of rivaroxaban on complications of catheter ablation for atrial fibrillation ,published in the Circulation Journal
    • 30 Aug 2017 Results a sub-analysis of JACRE Registry (n=1322; JACRE-R and JACRE-W )presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 25 Oct 2016 Results assessing safety and efficacy from Rivaroxaban cohort (JACRE-R) and Warfarin cohort (JACRE-W) studies published in the Circulation Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top